Department of Radiation Oncology, Institute of Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
J Nucl Med. 2010 May;51(5):713-9. doi: 10.2967/jnumed.109.071910. Epub 2010 Apr 15.
Accelerated tumor cell repopulation is an important mechanism adversely affecting therapeutic outcome in head and neck cancer. The noninvasive assessment of the proliferative state of a tumor by PET may provide a selection tool for customized treatment. 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) is a PET tracer that is phosphorylated by thymidine kinase 1 (TK-1) and, as such, reflects cellular proliferation. Before the use of (18)F-FLT PET for tumor characterization is accepted and introduced into clinical studies, validation against tumor histology is mandatory. The aim of this study was to validate (18)F-FLT PET in squamous cell carcinomas of the oral cavity using immunohistochemical staining for the proliferation marker iododeoxyuridine and for TK-1.
Seventeen patients with primary squamous cell carcinomas of the oral cavity underwent an (18)F-FLT PET/CT scan before surgery, and iododeoxyuridine was administered 20 min before tumor resection. (18)F-FLT PET/CT scans were segmented, and PET/CT volumes and PET signal intensities were calculated (mean standardized uptake value [SUV(mean)] and maximum standardized uptake value [SUV(max)]). Multiple paraffin-embedded tumor sections were immunohistochemically stained for iododeoxyuridine and TK-1. For iododeoxyuridine, labeling indices and optical densities were calculated and correlated with SUV(mean) and SUV(max). TK-1 staining was visually and semiquantitatively assessed.
All primary tumors were identified with (18)F-FLT PET but with a large range in tracer uptake (mean SUV(max), 5.9; range, 2.2-15.2). Also, there was a large variability in iododeoxyuridine labeling indices (mean, 0.09; range, 0.01-0.29) and optical densities (mean, 28.2; range, 12.6-37.8). The iododeoxyuridine optical densities correlated significantly with SUV(mean) and SUV(max), but the labeling indices did not. In most tumors, TK-1 staining of varying intensity was present but correlated with neither iododeoxyuridine binding nor (18)F-FLT uptake.
The current study demonstrated only a weak correlation between (18)F-FLT uptake and iododeoxyuridine staining intensity in oral cavity tumors. This weak correlation may be explained by differences in biomarker characteristics, resolution, and quantification methods.
使用增殖标志物碘脱氧尿苷(iododeoxyuridine)和胸苷激酶 1(thymidine kinase 1,TK-1)的免疫组织化学染色,验证口腔鳞状细胞癌中 3'-去氧-3'-[18F]氟代胸腺嘧啶(3'-deoxy-3'-(18)F-fluorothymidine,(18)F-FLT)正电子发射断层扫描(positron emission tomography,PET)在肿瘤特征描述中的应用。
17 例口腔原发性鳞状细胞癌患者在手术前进行了 (18)F-FLT PET/CT 扫描,并在肿瘤切除前 20 分钟给予碘脱氧尿苷。对 (18)F-FLT PET/CT 扫描进行分割,并计算 PET/CT 容积和 PET 信号强度(平均标准化摄取值[mean standardized uptake value,SUV(mean)]和最大标准化摄取值[SUV(max)])。对多个石蜡包埋的肿瘤切片进行碘脱氧尿苷和 TK-1 的免疫组织化学染色。对于碘脱氧尿苷,计算标记指数和光密度,并与 SUV(mean)和 SUV(max)相关。TK-1 染色进行了视觉和半定量评估。
所有原发性肿瘤均通过 (18)F-FLT PET 检测到,但示踪剂摄取范围较大(SUV(max)平均值为 5.9,范围为 2.2-15.2)。碘脱氧尿苷标记指数(mean 0.09,范围 0.01-0.29)和光密度(mean 28.2,范围 12.6-37.8)也存在很大的变异性。碘脱氧尿苷光密度与 SUV(mean)和 SUV(max)呈显著相关,但标记指数则不然。在大多数肿瘤中,存在不同强度的 TK-1 染色,但与碘脱氧尿苷结合或 (18)F-FLT 摄取均无相关性。
本研究仅在口腔肿瘤中观察到 (18)F-FLT 摄取与碘脱氧尿苷染色强度之间存在微弱的相关性。这种弱相关性可能是由于生物标志物特征、分辨率和定量方法的差异所致。